Cantor Fitzgerald analyst, William Tanner, reiterated his Overweight rating on shares of TherapeuticsMD (NYSE: TXMD) and views the probability that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE